Agoracom Blog Home

Posts Tagged ‘weed’

« Older Entries
Newer Entries »

North Bud Farms $NBUD.ca Provides Corporate Update $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 4:18 PM on Thursday, November 22nd, 2018

Northbud large

  • Construction cannabis production facility in Low, Quebec remains on schedule as per the timeline provided from our builder NGA Construction
  • Erecting of the steel structure began on the 19th of November and is expected to take approximately 30 days to complete
  • Company expects the building to be operational in Q1 2019

TORONTO, Nov. 22, 2018 — North Bud Farms Inc. (CSE: NBUD) (“NORTHBUD” or the “Company”) is pleased to provide shareholders with an update on our corporate activities.

Construction of our Cannabis Production Facility in Low, Quebec
NORTHBUD is pleased to update shareholders that the construction of our cannabis production facility in Low, Quebec remains on schedule as per the timeline provided from our builder NGA Construction. Erecting of the steel structure began on the 19th of November and is expected to take approximately 30 days to complete. We expect the building to be operational in Q1 2019. Please follow our social media channels for video updates of the facility construction (https://vimeo.com/302330795) and branding out reach.

Cannabis Act Application
Migration of the application to the Cannabis Licensing Tracking System (“CLTS”) has begun in collaboration with Cannabis Consulting Inc., one of the leading consultancy firms in the industry.

Update on Janey’s Inc. Acquisition
NORTHBUD and Janey’s continue to work on finalizing the acquisition agreement to include additional product segments. To date Janey’s has fulfilled multiple orders to the Ontario Cannabis Store and intends to expand its offering in the upcoming product calls.

Corporate Initiatives
NORTHBUD wishes to inform shareholders that its Board of Directors has approved management’s request to explore business opportunities in other international jurisdictions.

“This development represents an evolution in our business since going public and we feel it is important to update shareholders and potential shareholders that we will be actively pursuing international opportunities that we believe are complementary to our core business and that should create value for shareholders as we expand NORTHBUD’s global presence,” said Ryan Brown, CEO of North Bud Farms Inc.

About North Bud Farms Inc.
North Bud Farms Inc., through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR).   North Bud Farms will be constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.

For more information visit: www.northbud.com.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms’ final long form prospectus dated August 21, 2018 which is available under the issuer’s SEDAR profile at www.sedar.com.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected]

Tags: , , , , , , ,
Posted in All Recent Posts, Featured, North Bud Farms Inc | Comments Off on North Bud Farms $NBUD.ca Provides Corporate Update $ACB $WEED.ca $HIP.ca

Expect Supply Issues for Canadian Pot On Stronger than Expected Demand – SPONSOR: North Bud Farms $NBUD.ca

Posted by AGORACOM-JC at 2:59 PM on Thursday, November 22nd, 2018

SPONSOR: North Bud Farms Inc. (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Click Here For More Information

  • As Canada battles a nationwide marijuana shortage, Massachusetts dispensaries opened to recreational users on Tuesday.
  • Regulatory bottlenecks and unforeseen demand have caused disruptions in Canada’s marijuana supply ー but don’t expect the trouble to cease next year.

By Chloe Aiello

As Canada battles a nationwide marijuana shortage, Massachusetts dispensaries opened to recreational users on Tuesday.

Regulatory bottlenecks and unforeseen demand have caused disruptions in Canada’s marijuana supply ー but don’t expect the trouble to cease next year.

Khurram Malik, CEO of cannabis supplier Biome Grow, said he expects current supply issues to resolve soon, but he anticipates disorder in Canadian cannabis well into 2019.

Next year “is going to be a period of intermittent supply issues. What I mean by intermittent is you may have your favorite strain available one day, but not potentially two or three weeks down the line, and you’ll have to wait again for it,” Malik told Cheddar on Tuesday.

“But it won’t be a sky-is-falling scenario, like we’re seeing right now, where you just have completely empty store shelves in a variety of provinces,” he added.

Cannabis shortages across Canada have forced dispensaries to shutter only weeks out from recreational marijuana legalization. The shortages threaten to undermine legalization’s aim of quashing the illegal drug trade, as some frustrated customers return to their black market dealers, The New York Times reported.

Unexpected demand has contributed to bare shelves across the country, but so too have functional issues and regulatory red tape.

Issues ranging from delays in sales permits to cultivation licensing to shortages in excise stamps and packaging have contributed to the problem, Malik said.

“The problem in Canada … is it takes a while from a facility coming online to actually getting product out the door. There is a lot of regulatory things you have to jump through to prove you can actually start selling cannabis,” Malik said. “We don’t expect complete supply and demand to be sort of normalized until late 2019 or early 2020. Until then, you’ll see these intermittent issues.”

One day out, Massachusetts’ adult use marijuana supply seems to be fine, but Boston.com reporter Nikolas DeCosta-Kilpa said there has been some worry about supply issues, as the dispensaries work to build up their inventories.

“In Massachusetts, at least initially, the retail stores that are going to get into the adult use marijuana business are existing medical marijuana dispensaries, and they legally have to keep a certain percentage … of their inventory for their medical patients,” DeCosta-Kilpa said.

Massachusetts became the first East Coast state to legalize recreational marijuana in the U.S. Customers over 21 waited up to three hours at a time to ride the Massachusetts green wave, which kicked off at the only two dispensaries currently licensed to sell. Cultivate in Leicester, Mass., served served more than 500 customers within the first two hours of recreational sales, according to Boston.com.

Source: https://cheddar.com/videos/canada-faces-cannabis-supply-shortage-after-legalization

Tags: , , , , ,
Posted in All Recent Posts, North Bud Farms Inc | Comments Off on Expect Supply Issues for Canadian Pot On Stronger than Expected Demand – SPONSOR: North Bud Farms $NBUD.ca

CLIENT FEATURE: North Bud Farms $NBUD.ca sustainable low cost, high quality cannabinoid production and procurement $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 12:26 PM on Wednesday, November 21st, 2018

WHY NORTHBUD FARMS?

  • Canadian regulatory door for CIP (Cannabinoid Infused Products) is opening in 2019
    As shown in other legal jurisdictions (Colorado, Washington, Nevada, California)
  • Infused products sector has become the highest margin segment of the industry
  • Positioned to be a raw input producer for this space
  • Currently working with multiple food, beverage and science companies to provide safe standardized cannabinoid infused raw inputs for large scale GMP manufacturing of products
  • Announced Creation of “1017” Distribution and Signing of a LOI to Acquire Janey’s Cannabis Line

THE OPPORTUNITY

  • Acquired late stage ACMPR applicant GrowPros
    MMP from Tetra Bio-Pharma (TSXV: TBP)
  • GrowPros MMP application was submitted in November 2014 and is currently in the ‘Confirmation of Readiness’ stage.
  • Phase 1 is located on 95 acres of agricultural farmland in Low, Québec.
  • Option exists to acquire more land if needed
  • Facility will focus on GMP (higher production grade) pharma-grade cultivation and food-grade extracted inputs

 NORTHBUD October Construction Update. Everything is on schedule!

LOCATION

SITE DETAILS: LOW COST INFRASTRUCTURE

Construction of Facility

NORTHBUD and its team have been hard at work finalizing some minor design changes. NORTHBUD has received a detailed timeline for construction from our builder, NGA Construction Inc., and is on schedule to have the facility completed and an evidence package submitted to Health Canada in Q1 2019.

All infrastructure implementation has been completed and physical facility construction has begun.

ACMPR Application:

NORTHBUD, through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired from Tetra Bio-Pharma Inc. in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR).  In this regard, NORTHBUD has engaged Cannabis Compliance Inc. to assist in the migration of the ACMPR application to the CLTS which went into effect after the implementation of the Cannabis Act on October 17, 2018. NORTHBUD will be making amendments in order to take advantage of favourable changes that have been implemented under the Cannabis Act.

Hub On AGORACOM

FULL DISCLOSURE: North Bud Farms is an advertising client of AGORA Internet Relations Corp.

Tags: , , , , ,
Posted in AGORACOM Client Feature, All Recent Posts, North Bud Farms Inc | Comments Off on CLIENT FEATURE: North Bud Farms $NBUD.ca sustainable low cost, high quality cannabinoid production and procurement $ACB $WEED.ca $HIP.ca

Investment in Recreational #Marijuana on the Rise $BOG.ca $NBUD.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 1:58 PM on Tuesday, November 20th, 2018

 

  • Drink companies and other investors have begun making moves to profit from the cannabis industry through a series of M&A deals.
  • In Canada, the recent legislation of use of recreational cannabis use has given a boost to the adoption of the industry in North America, as well as the US midterms which saw Attorney General Jeff Sessions (opposed to legalization of cannabis) step down.

Jimmy Aki

In the United States, medical marijuana is currently legal in 30 states. Only nine states and Washington have legalized recreational marijuana for users above the age of 21 years.

Canada and America are very important for the growth of the industry as both countries currently contribute 90% of the global revenues. To take advantage of the sector, American companies have enlisted a little-known strategy known as ‘reverse merger’ to grow their operations.

Source: Shutterstock

Canadian Funds

Reverse Mergers, also known as Reverse Takeovers (RTO), are a speedy way of becoming a publicly traded company and have been on the increase due to the frenzy around the sector. They are used by private firms who acquire a publicly traded company (or a shell company), thereby becoming publicly traded without going through an Initial Public Offering (IPO).

For American firms, Canada remains a popular destination for raising capital, for an industry that is still federally illegal in the US. These firms going through this route can skip the troubles they would have faced if they had sought the traditional IPO route.

These include registration and vetting process from the Canadian Securities Administrators (Canada’s version of the SEC) and investment bankers, who will drill into the finances and barge the company with a ton of questions.

2018 has witnessed over 200 M&A deals in the cannabis sector, according to data from cannabis-focused analytical firm Virdian Capital Advisors. California based cannabis dispensary provider MedMen, whose high-end dispensaries have been compared to Apple stores, went public in May after purchasing Ladera Ventures—a Vancouver based oil and gas shell company, through an RTO.

The company also acquired PharmaCann in a $682 million stock transaction, doubling its market share overnight. MedMen’s competitor iAnthus has also been busy making deals, picking up Canadian diversified cannabis firm MPX Bioceutical in a major $640 million deal.

Entrant of Breweries

For an industry whose market cap was a little over $5 billion market in 2015, with an estimated projection expected to hit a conservative $20 billion by 2020, the market for the emerging cannabis sector can only get better.

The industry could witness an explosion when beverage companies make their long-expected entrance and replace part of their alcoholic content with cannabis. Last year, Constellation Brands, the makers of Corona beer, got into the action with a minority stake in Canadian marijuana producer Canopy Growth Corp.

Winnipeg brewery Fort Garry Brewing Co also joined forces with medical cannabis provider Delta 9 Cannabis to launch the “Legal Lager,” a beer filled with hemp seed.

According to the company’s press release at the time, the Legal Lager, which was released as “an ongoing research and development project to jointly produce a cannabis beer” that contains Tetrahydrocannabinol (THC), doesn’t contain:

“cannabis or any other psychoactive agent produced from the cannabis plant.”

Source: https://www.moneymakers.com/investment-in-recreational-marijuana-on-the-rise/

Tags: , , , , , ,
Posted in All Recent Posts, Bougainville Ventures, Marijuana Company of America, North Bud Farms Inc | Comments Off on Investment in Recreational #Marijuana on the Rise $BOG.ca $NBUD.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Marijuana Company of America $MCOA Announces Q3 Financial Results $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 9:30 AM on Tuesday, November 20th, 2018

15233 mcoa

  • Revenue up 2984% from Q3 2017 to Q3 2018
  • Company achieved a 1057% decrease in net loss from operations from Q3 2017 to Q3 2018
  • SG&A expenses decreased by 1007% from Q3 2017 to Q3 2018.
  • Total assets increased by 42% from Q3 2017 to Q3 2018.
  • Total liabilities decreased by 259% from Q3 2017 to Q3 2018.

Escondido, California–(November 20, 2018) – MARIJUANA COMPANY OF AMERICA INC. (OTC Pink: MCOA) (“MCOA” or the “Company”), an innovative hemp and cannabis corporation, is pleased to announce the financial results for the three and nine months ended September 30, 2018. Here are some of the notable highlights for the third quarter of FY2018:

• Total revenues were $90,276 for the three quarters ended September 30, 2018, as compared to $2,927 for the three quarters ended September 30, 2017, representing a 2984% increase quarter to quarter.

• The net loss from operations decreased by 1057% from $19,047,499 for the three quarters ended September 30, 2017, to $1,801,387 for the three quarters ended September 30, 2018.

• Gross profit for the third quarter of 2018 increased to $61,839 on gross sales of $90,276 (6.5% gross margin), compared to a gross margin for the third quarter of 2017 of $986.

• Including non-cash items and one-time transactional expenses, SG&A expenses for the third quarter of 2018 decreased substantially by $17,160,679 or 1007% to $1.89 million, compared to $17.2 million for the fourth quarter of 2017.

• For the third quarter ending September 30, 2018, the Company realized the following other one-time income items: Gain cancellation of debt of $1,500,000 and a gain of $1,175,000 from the change in value of its trading securities investment in Global Payout.

• Total assets increased by 42% from $1,129,958 for the three quarters ended September 30, 2017 to $2,694,929 for the three quarters ended September 30, 2018. This increase is due primarily to the increase in value of the Company’s investment in Global Payout’s stock, which is accounted for using the trading security method of accounting as well as an increase in inventory.

• Total liabilities decreased by 259% from $11,447,710 for the three quarters ended September 30, 2018 to $4,414,752 for the three quarters ended September 30, 2018. This decrease was largely due to the decrease in liabilities related to warrants and joint venture obligations.

• Cash used by operating activities for the three quarters ending September 30, 2018 was $1,010,520, compared to cash used for operating activities of $527,412 for the quarter ended September 30, 2017. Cash used by investing activities for the three quarters ending September 30, 2018 was $631,886, compared to $702,419 for the three quarters ended September 30, 2017. Cash provided by financing activities for the three quarters ending September 30, 2018 was $1,460,067, compared to $1,082,345 for the three quarters ended September 30, 2017.

“The third quarter marked an important milestone for MCOA, as our hempSMART sales have ramped up due to our multi-pronged marketing campaign and several newly launched products. We ended the quarter strong with a revenue trend that is now largely stabilized with the strong foundation that we built. We expect sales to continue to increase through Q4 with the holiday season and into next year with our European expansion,” said Don Steinberg, MCOA’s CEO.

Jesus Quintero, MCOA’s Chief Financial Officer, said, “The strength of the third quarter results including a substantial increase in consolidated revenue and achieving a stronger balance sheet illustrates execution of our strategic plan. MCOA is positioned to deliver on increasing levels of cash flow as we seek to stack profitable recurring revenue from our monthly autobill customers while seeking to streamline production and fulfillment costs for our products.”

Further details about the Company’s financial results are available in its annual report on Form 10K, which will be available in the investor relations section of the Company’s website at www.marijuanacompanyofamerica.com.

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our hempSMART Products Containing CBD

The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s juridiction.

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Tags: , , , , ,
Posted in All Recent Posts, Marijuana Company of America | Comments Off on Marijuana Company of America $MCOA Announces Q3 Financial Results $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Tetra Bio-Pharma $TBP.ca Enters into Binding Proposal with Quantum Pharma Inc. $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:18 AM on Tuesday, November 20th, 2018

Logo tetrabiopharma rgb web

  • Company takes a significant step forward to become a fully integrated drug development company
  • enables the company to produce cannabis and cannabinoid drug products for Tetra’s and Panag Pharma’s development activities including the ocular drug formulations
  • Quantum Pharma owned by Dr. Peter Ford was the GMP manufacturing division of Ford’s Family Pharmacy and Wellness Centre

ORLEANS, Ontario, Nov. 20, 2018 — Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF), and Quantum Pharma Inc. (“Quantum”) today announced the signing of a binding proposal (the “Proposal“) for exclusive access to a Health Canada licensed facility (i.e., Drug Establishment License; DEL) that enables the company to produce cannabis and cannabinoid drug products for Tetra’s and Panag Pharma’s development activities including the ocular drug formulations.   Quantum Pharma owned by Dr. Peter Ford was the GMP manufacturing division of Ford’s Family Pharmacy and Wellness Centre.  Their formulation expertise will enable Tetra to develop innovative products for future clinical trials. 

The Proposed Transaction is expected to provide Tetra with:

  • Exclusive access to a Health Canada licensed facility (DEL) to fabricate cannabis and cannabinoid drug products for Tetra and Panag’s development activities;
  • Cannabis and cannabinoid drug product formulation expertise; and
  • The ability to manufacture products for all its clinical trials and commercial launches.

Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma stated, “We are very pleased to announce this important development to our shareholders.  We have been working with Ford’s Family Pharmacy and Wellness Centre since 2016.  Dr. Peter Ford and his team have created several innovative formulations and instruments for the fabrication of Tetra’s prescription drugs.  This exclusive agreement not only secures the innovations and production know-how developed for Tetra, but also protects these assets from an acquisition by a competitor.  Quantum Pharma will be an exclusive partner to Tetra and Panag enabling us to execute our future planned trials as well as prepare for our product launches.”

Dr. Chamberland further stated, “Tetra has already entered into various agreements to ensure the supply meets the demand for cannabis, THC and CBD-based products with partners including Aphria Inc., True North Cannabis, a USA-based synthetic cannabinoid manufacturer and a phytocannabinoid supplier.  With the expected completion of the Panag acquisition, Tetra will become vertically integrated with drug development capabilities that range from discovery all the way through to commercial launch.  Our partnerships with Genacol Corporation and Kombucha Baby Brewing Company and its partners provides Tetra with a global sales and distribution platform for the commercialization of OTC drug and wellness products.  In addition, Tetra has also established distribution and sales agreements with two pharmaceutical companies for its PPP001 prescription drug product.”

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Health Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the successful integration of this acquisition,  the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]
Media Contact
energi PR
Carol Levine Stephanie Engel
514-288-8500 ext. 226 416-425-9143 ext. 209
[email protected] [email protected]

Tags: , , , , , , ,
Posted in All Recent Posts, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Enters into Binding Proposal with Quantum Pharma Inc. $AERO $CBDS $CGRW $APH.ca $GBLX

Canada facing #marijuana shortage following legalization $BOG.ca $NBUD.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 1:04 PM on Friday, November 16th, 2018

Uncertainty over future cannabis supplies sparks fears that buyers may return to black market

Canada is running low on supplies of legal cannabis a month after laws allowing the recreational use of the drug kicked in.

According to a poll by the non-profit Angus Reid Institute, one in eight Canadians has used marijuana since it was legalised on 17 October. But with demand outstripping supply in the new regulated market, authorities fears some users may return to buying from illegal dealers.

Khurram Malik, CEO of Toronto-based cannabis company Biome Grow Inc, told Canada’s Global News that the shortages are the result of the government’s strict controls on marijuana, and the resulting time it takes for producers to develop a compliant product.

All private retailers are required to pass extensive background checks, and approved operators must order their cannabis through suppliers regulated by the provincial government.

“The rules here are so difficult to grow cannabis, quite frankly more difficult than anyone else in the world,” said Malik.

Even companies that stockpiled supplies of marijuana before it was legalised are now reporting shortages.

James Burns, CEO of Alcanna, an off-licence chain that sells the drug in the province of Alberta, told the BBC that the provincial supplier, the Alberta Gaming, Liquor and Cannabis Commission (AGLC), is out of stock on most cannabis products.

“It doesn’t matter how big you are, there’s just none there. If the government warehouse is empty, it’s empty. There’s nothing you can do,” he said.

Source: https://www.theweek.co.uk/cannabis/97848/canada-facing-marijuana-shortage-after-legislation

Tags: , , , , ,
Posted in All Recent Posts, Bougainville Ventures, Marijuana Company of America | Comments Off on Canada facing #marijuana shortage following legalization $BOG.ca $NBUD.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Harvest Update at Marijuana Company of America’s $MCOA #CBD Hemp Project in New Brunswick $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 5:19 PM on Thursday, November 15th, 2018

15233 mcoa

  • The 2018 cultivation consisted of 125 acres contracted from four farmers in the northeast region of NB, utilizing three Health Canada approved cultivars with an expected CBD content of 1.5% to 2.5%.
  • This group of enthusiastic and innovative farmers was of great assistance to the project over the course of the season.

ESCONDIDO, Calif., Nov. 15, 2018 – via NetworkWire – MARIJUANA COMPANY OF AMERICA INC. (“MCOA” or the “Company”) (OTC: MCOA), an innovative hemp and cannabis corporation, and its joint venture partner Global Hemp Group Inc. (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) (the “Partners”) wish to provide an update on the harvest at their CBD hemp project in New Brunswick (“NB”), Canada.

The 2018 cultivation consisted of 125 acres contracted from four farmers in the northeast region of NB, utilizing three Health Canada approved cultivars with an expected CBD content of 1.5% to 2.5%. This group of enthusiastic and innovative farmers was of great assistance to the project over the course of the season. Harvesting of hemp for cannabinoid extraction required some innovation to handle both the harvesting and initial processing of the hemp. Dr. Paul Perrault, GHG Director and New Brunswick Project Manager stated, “We want to thank the farmers for their creativity and willingness to find solutions to the challenges that arose as we worked through the harvesting and drying process for this year’s cultivation.”

The harvest in NB has been completed. In order to process the hemp for cannabidiol (“CBD”) the first step in the process is drying the biomass. The team set up three drying facilities, the main industrial-scale biomass dryer located at the group’s facility in Bathurst (as announced August 30, 2018), and two smaller refurbished tobacco kilns were installed onsite at two of the farms. The auxiliary drying units installed on the farms arrived later in the season are currently being made ready to be operational for use in the 2019 growing season.

The Partners now have 17.5 tonnes of dried biomass in storage from this year’s harvest, a yield lower than expected due to weather issues, some minor pest issues and a bottleneck in processing the harvested hemp material. In order to address the processing issues encountered in this year’s operations, members of the engineering department of the Collège Communautaire du Nouveau Brunswick (CCNB) were brought in to assist in identifying solutions to expedite harvesting and increase efficiency in the processing of the hemp. With the assistance of CCNB we expect to improve the harvesting system to minimize straw intake at harvest and to adapt the tobacco kilns to processing hemp tops. Discussions are underway with CCNB to formalize this collaboration around two projects on harvesting and processing which will involve the current group farmers. Their experience will be invaluable in this research.  In addition, with the advent of the additional tobacco dryers, decentralized drying and storage at the farm level will be introduced for the 2019 cultivation. Such additional dryer capacity at the farm level will reduce the drying bottleneck experienced this year and will minimize the Company’s carbon footprint by significantly reducing the transport cost of moving tons of moisture laden material.

The Partners are now evaluating how best to monetize this year’s harvest. At this point they have had discussions with a number of potential purchasers of the biomass.

The 2018 hemp cultivation provided the group with a tremendous amount of knowledge and experience from this year’s larger scale operation. The Partners continue to be committed to hemp cultivation and processing in northeastern New Brunswick. We are convinced significantly better results can be achieved with improved genetics and further refinement of farming and processing practices. Industrial hemp cultivars containing 4-5% CBD already on trial in NB would more than double the performance of current cultivars used in 2018, but have not yet been registered for use as a Health Canada approved cultivar.

About Marijuana Company of America, Inc.
MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™â€, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our hempSMART Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWire/MCOA

Corporate Communications Contact: 
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Tags: , , , , ,
Posted in All Recent Posts, Marijuana Company of America | Comments Off on Harvest Update at Marijuana Company of America’s $MCOA #CBD Hemp Project in New Brunswick $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Tetra Bio-Pharma $TBP.ca Pilot Study to Investigate a Cannabinoid Derived Drug in Dogs $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:55 AM on Thursday, November 15th, 2018

Logo tetrabiopharma rgb web

Tetra Bio-Pharma and Panag Pharma Advance their Veterinary Drug Pipeline 

  • Announced the submission of a clinical research application to the Veterinary Drugs Directorate at Health Canada.
  • This first of a kind veterinary study will examine the use of a cannabinoid-based drug to treat ocular pain and inflammation in canines
  • The pilot study will be led by veterinary ocular care specialists

ORLEANS, Ontario, Nov. 15, 2018 — Tetra Bio-Pharma Inc. (“Tetra” or “TBP”) (TSX VENTURE: TBP) (OTCQB: TBPMF) and Panag Pharma Inc. (“Panag”) today announced the submission of a clinical research application to the Veterinary Drugs Directorate at Health Canada. This first of a kind veterinary study will examine the use of a cannabinoid-based drug to treat ocular pain and inflammation in canines. The pilot study will be led by veterinary ocular care specialists.

“Several companies are marketing cannabis-based treatments for aliments in companion animals, but there is a major gap in understanding the safety and efficacy of these drugs,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma. “This study demonstrates our commitment to becoming a world leader in the field of cannabinoid-based therapies for vision health. Tetra continues to adhere to an evidence-based drug development model, consistent with bringing novel, efficacious and safe drug products to market, including the veterinary market. We look forward to launching this trial to investigate the use of cannabinoids to treat eye pain and inflammation in dogs.”

In addition to the pharmaceutical and natural health products markets, Tetra will also launch trials in the companion animal market.  If approved, these products will be destined for global sales. At present, world-wide revenues derived from the companion animal market exceeded $30 billion in 2017, and this is expected to grow to $41 billion by 2024.

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including this trial, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tags: , , , , , ,
Posted in All Recent Posts, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Pilot Study to Investigate a Cannabinoid Derived Drug in Dogs $AERO $CBDS $CGRW $APH.ca $GBLX

Revenues at #Cannabis Startups Surge as Demand Begins to Outstrip Supply $BOG.ca $NBUD.ca $MCOA $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 10:51 AM on Wednesday, November 14th, 2018

By Kevin Kelleher

7:30 PM EST

Three of the largest cannabis companies reported earnings this week, painting a portrait of a nascent industry enjoying surging demand as recreational pot becomes legalized in more places—but they’re also encountering some growing pains.

Aurora Cannabis said Monday its revenue rose 260% to $29.7 million Canadian dollars (US$22 million). Net income came in at C$105.5 million, up from C$3.56 million a year ago, largely because of unrealized gains on securities.

On Tuesday, Tilray said revenue rose 86% to C$10 million, while its net loss increased to C$19 million from C$1.8 million a year ago, driven largely by an increase in non-cash stock-based compensation charges.

Also on Tuesday, Cronos Group said revenue in the third quarter rose 186% to C$3.8 million, compared with C$1.3 million a year ago. Cronos lost 4 Canadian cents per share.

Both Tilray and Cronos said that the average price of weed per gram declined. Tilray attributed the decline to an increase in bulk sales as a percentage of total revenue.

However, the price of cannabis could increase in the future because demand is beginning to outstrip supply as Canada and many U.S. states have legalized marijuana. Much of the cannabis sales the three companies reported last quarter came from medicinal marijuana.

“Similar to other Canadian LPs, we are facing demand that outstrips supply,” Aurora’s chief corporate officer Cam Battley said during the company’s earnings conference call. “We anticipate this dynamic to continue for some time.”

Cannabis stocks surged through most of 2018 before encountering a selloff, once pot became legal in Canada, in a classic buy-on-rumor, sell-on-news scenario. Investors appear to be remaining cautious, despite the strong revenue growth last quarter. On Tuesday, Aurora’s stock on the NYSE fell 3.7%, while TIlray fell 1.9% and Cronos fell 1.7%.

Source: http://fortune.com/2018/11/13/revenue-cannabis-startups-surges-demand-outstrip-supply/

Tags: , , , , , , , ,
Posted in All Recent Posts, Bougainville Ventures, Marijuana Company of America, North Bud Farms Inc | Comments Off on Revenues at #Cannabis Startups Surge as Demand Begins to Outstrip Supply $BOG.ca $NBUD.ca $MCOA $ACG.ca $ACB $WEED.ca $HIP.ca

« Older Entries
Newer Entries »